3月17日讯,日内瓦药品专利池(Medicines PatentPool, MPP)组织宣布,上海迪赛诺、华海药业、普洛药业、复星医药、九洲药业这五家中国药企进入辉瑞新冠口服药Paxlovid的“特仿”名单。在新冠疫情仍被定义为突发公共卫生事件期间,它们可以免专利费生产Paxlovid的核心成分奈玛特韦(nirmatrelvir)。其中,九洲药业仅生产原料药,另外4家可同时生产原料药和制剂。
老虎资讯综合2022-03-17
3月17日讯,日内瓦药品专利池(Medicines PatentPool, MPP)组织宣布,上海迪赛诺、华海药业、普洛药业、复星医药、九洲药业这五家中国药企进入辉瑞新冠口服药Paxlovid的“特仿”名单。在新冠疫情仍被定义为突发公共卫生事件期间,它们可以免专利费生产Paxlovid的核心成分奈玛特韦(nirmatrelvir)。其中,九洲药业仅生产原料药,另外4家可同时生产原料药和制剂。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email:uservice@ttm.financial